Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes.

ABSTRACT:

Introduction

Dapagliflozin is an orally administered selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin lowers blood glucose through a reduction in renal glucose reabsorption. This study was performed to assess the effect of the oral antidiabetic agent voglibose [0.2 mg thrice daily (t.i.d.)] at steady-state, on the pharmacokinetics, safety and tolerability of dapagliflozin administered as a single oral dose (10 mg) to Japanese patients with T2DM.

Methods

This was an open-label, multi-center, drug-drug interaction study. A single oral dose of dapagliflozin (10 mg) was administered to 22 Japanese patients with T2DM in the presence and absence of voglibose (0.2 mg t.i.d.). Serial bloo

SUBMITTER: Imamura A 

PROVIDER: S-EPMC3687097 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature